Rola Al Dhaybi1, Mehdi Agoumi2, Isabelle Gagné2, Catherine McCuaig3, Julie Powell3, Victor Kokta2. 1. Division of Dermatology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada. Electronic address: roladhaybi@yahoo.com. 2. Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada. 3. Division of Dermatology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
Abstract
BACKGROUND: Childhood malignant melanomas frequently present as nodular melanomas with Spitzoid features. Spitz nevus and Spitzoid melanoma overlap clinically and histopathologically and there have been many attempts to differentiate between them. Spitz nevi differ from melanomas by their immunohistochemical pattern of expression of cell cycle and apoptosis regulators such as the p16 protein. OBJECTIVE: The aim of this study was to evaluate in a childhood population the expression of p16 in nodular malignant melanoma of Spitzoid type, Spitz nevi, and a control group of benign compound melanocytic nevi. METHODS: We performed immunohistochemical studies for expression of p16 in 6 Spitzoid malignant melanomas, 18 Spitz nevi, and 12 compound melanocytic nevi in children younger than 18 years. Statistical analysis was used to compare p16 expression, mitotic count/mm(2), and Ki-67 index of childhood nodular malignant melanomas and Spitz nevi. RESULTS: All the childhood melanoma cases were associated with loss of p16 without any correlation with their Breslow thickness whereas all the Spitz nevi and benign melanocytic nevi had strong positive nuclear and cytoplasmic expression of p16 staining. We found a statistically significant difference in p16 expression, mitotic counts, and Ki-67 index when comparing the Spitzoid melanomas with the Spitz nevi. LIMITATIONS: This study is limited by the small number of malignant melanomas, which are known to be rare in childhood. CONCLUSION: p16 Expression in childhood nodular Spitzoid malignant melanomas and Spitz nevi, in conjunction with clinical and histopathological evaluation, may be a useful tool in differentiating between these two entities.
BACKGROUND: Childhood malignant melanomas frequently present as nodular melanomas with Spitzoid features. Spitz nevus and Spitzoid melanoma overlap clinically and histopathologically and there have been many attempts to differentiate between them. Spitz nevi differ from melanomas by their immunohistochemical pattern of expression of cell cycle and apoptosis regulators such as the p16 protein. OBJECTIVE: The aim of this study was to evaluate in a childhood population the expression of p16 in nodular malignant melanoma of Spitzoid type, Spitz nevi, and a control group of benign compound melanocytic nevi. METHODS: We performed immunohistochemical studies for expression of p16 in 6 Spitzoidmalignant melanomas, 18 Spitz nevi, and 12 compound melanocytic nevi in children younger than 18 years. Statistical analysis was used to compare p16 expression, mitotic count/mm(2), and Ki-67 index of childhood nodular malignant melanomas and Spitz nevi. RESULTS: All the childhood melanoma cases were associated with loss of p16 without any correlation with their Breslow thickness whereas all the Spitz nevi and benign melanocytic nevi had strong positive nuclear and cytoplasmic expression of p16 staining. We found a statistically significant difference in p16 expression, mitotic counts, and Ki-67 index when comparing the Spitzoid melanomas with the Spitz nevi. LIMITATIONS: This study is limited by the small number of malignant melanomas, which are known to be rare in childhood. CONCLUSION:p16 Expression in childhood nodular Spitzoid malignant melanomas and Spitz nevi, in conjunction with clinical and histopathological evaluation, may be a useful tool in differentiating between these two entities.
Authors: D W Bartenstein; J M Fisher; C Stamoulis; C Weldon; J T Huang; S E Gellis; M G Liang; B Schmidt; E B Hawryluk Journal: Br J Dermatol Date: 2019-02-10 Impact factor: 9.302
Authors: Anna Eisenstein; Izabela P Panova; Hye J Chung; Lynne J Goldberg; Qing Zhang; Rossitza Lazova; Jag Bhawan; Klaus J Busam; James T Symanowski; Rhoda M Alani; Byungwoo Ryu Journal: Melanoma Res Date: 2018-02 Impact factor: 3.599
Authors: Damon Reed; Ragini Kudchadkar; Jonathan S Zager; Vernon K Sondak; Jane L Messina Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: James V Tricoli; Donald G Blair; Carey K Anders; W Archie Bleyer; Lisa A Boardman; Javed Khan; Shivaani Kummar; Brandon Hayes-Lattin; Stephen P Hunger; Melinda Merchant; Nita L Seibel; Magdalena Thurin; Cheryl L Willman Journal: Cancer Date: 2016-02-05 Impact factor: 6.860
Authors: Sophia A Ma; Conor P O'Day; Tzvete Dentchev; Junko Takeshita; Todd W Ridky; John T Seykora; Emily Y Chu Journal: J Cutan Pathol Date: 2019-02-14 Impact factor: 1.587